<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="741">
  <stage>Registered</stage>
  <submitdate>15/09/2005</submitdate>
  <approvaldate>25/10/2005</approvaldate>
  <actrnumber>ACTRN12605000690651</actrnumber>
  <trial_identification>
    <studytitle>Effect of Rosiglitazone on Vascular Function in Patients with Advanced Chronic Kidney Disease</studytitle>
    <scientifictitle>The Effect of Rosiglitazone on Vascular Function in Patients with Advanced Chronic Kidney Disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Chronic kidney disease</healthcondition>
    <healthcondition>Vascular function</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Randomised, double blind, placebo-controlled, parallel-group study of rosiglitazone 4mg/day vs placebo for 8 weeks</interventions>
    <comparator>matching placebo given orally for 8 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. Post-ischaemic flow-mediated dilatation of the brachial artery.</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Systemic arterial compliance (a measure of arterial elasticity)</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>3. Augmentation Index (a measure of arterial stiffness)</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Pulse wave velocity and pulse wave velocity index</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Insulin sensitivity as measured by a euglycaemic clamp and the HOMA score</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, apolipoprotein B, and AI concentration</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Markers of inflammation (CRP, IL-6) and thrombosis (fibrinogen, plasminogen activator inhibitor - PAI-1).</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. 24-hour ambulatory blood pressure</outcome>
      <timepoint>After 8 weeks of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients on haemodialysis or peritoneal dialysis for Chronic kidney disease, Patients should be stable on dialysis for at least 6 months with adequate indices of dialysis (Fractional Reduction of Urea, FRU &gt; 0.67 or Kt/V &gt; 0.3); All patients with moderate-to-severe stages 3-5 chronic kidney disease (GFR &lt; 60ml/min); Patients will be selected for having the Metabolic Syndrome as defined by the WHO criteria [31] based on our previous data showing that these patients had markedly impaired vascular function:1. Insulin resistance identified by 1 of the following: Type 2 diabetes, impaired fasting glucose &gt; 6.1 mmol/L, impaired glucose tolerance or increased fasting insulin &gt; 75th percentile for the population (8 mU/L).PLUS ANY 2 OF THE FOLLOWING:1. Antihypertensive medication and/or systolic blood pressure &gt;= 140mmHg or diastolic blood pressure &gt;= 90 mmHg.2. Plasma triglycerides &gt; 1.7 mmol/L3. HDL-cholesterol &lt; 0.9 mmol/L in men and &lt; 1.0 mmol/L in women4. Body mass index &gt; 30 kg/m2 and/or waist:hip ratio &gt; 0.9 in men and 0.85 in women5. Urinary albumin excretion rate &gt;= 20 microg/min. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Type 1 diabetes mellitus; Nephrotic-range proteinuria; Liver enzymes &gt; 2 times upper limit of normal; Alcohol consumption &gt; 3 standard drinks/day; Immunosuppressive therapy for renal transplantation; Cardiovascular event or unstable cardiovascular disease in preceding 6 months; Symptomatic or NYHA heart failure stage III or IV; Hb &lt; 110g/L; Significant psychiatric disorder; Active infection or inflammation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation by a distant unit (pharmacy)</concealment>
    <sequence>Computer generated random sequence with Block randomisation substratified for dialysis mode or predialysis, and for presence or absence of diabetes</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Raine Medical Research foundation (pending)</primarysponsorname>
    <primarysponsoraddress>Raine Medical Research Foundation
Suite 24, Hollywood Specialist Centre
95 Monash Ave
Nedlands WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Raine Medical Research foundation</fundingname>
      <fundingaddress>Raine Medical Research Foundation
Suite 24, Hollywood Specialist Centre
95 Monash Ave
Nedlands WA 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>GlaxoSmithKline Australia</fundingname>
      <fundingaddress>1061 Mountain Highway
Boronia, Victoria 3155</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Western Australia School of Medicine and Pharmacology</sponsorname>
      <sponsoraddress>Rear 50 Murray Streeet
Perth WA 6000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sharan Dogra</name>
      <address>University of Western Australia
Medical Research Foundation Building
Level 3
Rear 50 Murray Street 
Perth WA 6000</address>
      <phone>+61 8 92240232</phone>
      <fax />
      <email>sdogra@meddent.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Doris Chan</name>
      <address>Department of Nephrology
Royal Perth Hospital
Wellington Street Campus
Perth WA 6000</address>
      <phone>+61 8 92242244</phone>
      <fax />
      <email>doris.chan@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>